UPDATE: BMC Initiates Optimer Pharmaceuticals at Buy

BMC is out with its report today on Optimer Pharmaceuticals OPTR, initiating OPTR at Buy. In its report, BMC writes, "We are initiating coverage of Optimer Pharmaceuticals with a Buy Rating and a $20 target price. Our positive opinion is based primarily on the opportunity for the company's newly launched antibiotic, Dificid, to exceed sales expectations in the near and longer term." Shares of OPTR closed Tuesday at $16.12, up 2.94% from Monday's close.